Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

aTYR PHARMA (ATYR) Revenue (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Revenue for 6 consecutive years, with $190000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Revenue changed N/A year-over-year to $190000.0, compared with a TTM value of $190000.0 through Dec 2025, down 19.15%, and an annual FY2025 reading of $190000.0, down 19.15% over the prior year.
  • Revenue was $190000.0 for Q3 2025 at aTYR PHARMA, down from $235000.0 in the prior quarter.
  • Across five years, Revenue topped out at $10.4 million in Q4 2022 and bottomed at $190000.0 in Q3 2025.
  • Average Revenue over 4 years is $2.8 million, with a median of $294000.0 recorded in 2023.